Abstract
A retrospective chart review was performed at 3 Swedish hospitals to evaluate the utilization, outcomes, and cost of using epoetin alfa or darbepoetin alfa to treat cancer patients with chemotherapy-related anemia. Data on dosage, duration of treatment, hematologic response, red blood cell transfusions, and healthcare resource consumption were collected and analyzed at various time points following the initiation of drug therapy. A significantly faster hematologic response and increase in hemoglobin were observed in patients treated with epoetin alfa. Dosages used in clinical practice appeared to be lower than those recommended by Swedish treatment guidelines. There were no significant differences in resource utilization or healthcare costs between the 2 treatment groups. By day 112, the mean treatment cost per patient, in Swedish kronors (SEK), was SEK74,701 (~US$9800 or E8300) with epoetin alfa and SEK85,285 (~US$11,000 or E9500) with darbepoetin alfa. Drug acquisition and administration accounted for 81 % and 67% of the total cost of epoetin alfa and darbepoetin alfa therapy, respectively; the remainder of the total cost was for hospitalization and transfusions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment.J Natl Cancer Inst. 1999;91:1616–1634.
Ludwig H, Birgegard G, Barrett-Lee P, Krzakowski M. Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European Cancer Anaemia Survey (ECAS) [abstract].Blood. 2002;100(11 pt 1):234a-235a. Abstract 884.
Abels R. Erythropoietin for anaemia in cancer patients.Eur J Cancer. 1993;29A(suppl 2):S2-S8.
Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.J Clin Oncol. 2001;19:2865–2874.
Dammaco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.Br J Haematol. 2001;113:172–179.
Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.J Natl Cancer Inst. 2002;94:1211–1220.
Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.Br J Haematol. 2003;122:394–403.
Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomized study.Eur J Cancer. 2003;39:2026–2034.
Rutten-van Mölken MPMH, van Doorslaer EKA, van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial.Health Econ. 1994;3:333–345.
FASS (Swedish Pharmacopoeia). Stockholm, Sweden: Linfo; 2003 [in Swedish].
Swedish Drug Market, SDM Q2 2002. CDROM, Läkemedelsstatistik AB, Stockholm, 2002.
Jeppsson, B. Prislista, regionala priser och ersättningar 2003 för Södra sjukvårdsregionen. Available at: http://www.srvn.org/pris03/1-88.pdf. Accessed October 10, 2003.
Manly BFJ.Multivariate Statistical Methods: A Primer. London, England: Chapman & Hall; 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persson, U., Borg, S., Jansson, S. et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response. Adv Therapy 22, 208–224 (2005). https://doi.org/10.1007/BF02849930
Issue Date:
DOI: https://doi.org/10.1007/BF02849930